InvestorsHub Logo
Post# of 249979
Next 10
Followers 788
Posts 118630
Boards Moderated 15
Alias Born 09/05/2002

Re: DewDiligence post# 220075

Thursday, 10/11/2018 5:17:19 PM

Thursday, October 11, 2018 5:17:19 PM

Post# of 249979
ABBV settles global Humira-patent litigation with NVS:

The 9/30/23 launch date in the US market is 2 months later than MYL’s launch date (#msg-142251299), 3 months later than Samsung’s launch date (#msg-139804103), and 8 months later than AMGN’s launch date (#msg-134976468).

I.e. AMGN, the first company to settle with ABBV, got a 6-month head start in the US market relative to all other Humira biosimilars; the settlements from the second to the fourth (and presumably additional ones to come) have US launch spaced 1 month apart, so there’s a tangible disincentive to the settling companies for waiting.

MNTA has not yet settled with ABBV.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.